DALLAS, May 07, 2019 (GLOBE NEWSWIRE) — via OTC PR WIRE — Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced CEO Frederick Ferri is leading a site survey today of the cannabis extraction lab KALY is building in partnership with Nouveau (USOTC: NOUV) (“NOUV”) to facilitate extraction in conjunction with NOUV’s previously announced 100 acer hemp farm. NOUV currently operates a 25-greenhouse growing operation and in partnership with KALY plans to build an additional state-of-the-art greenhouse for the purpose of developing a proprietary cannabis cultivar.
Patented Cannabis Extracts Targeting $170 In Million Pharmaceutical Treatments
In the fourth quarter of last year, 2018, KALY acquired NCM Biotech (NCMB). NCMB is biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from a proprietary cannabinoid product platform in a broad range of disease areas. In four years of operations, the company has established a leading position in the development of plant-derived cannabinoid therapeutics through a proven drug discovery and patented development process. The resulting intellectual property portfolio and the established regulatory and manufacturing expertise have created a significant opportunity. KALY, through its subsidiary, NCMB has a deep pipeline of additional cannabinoid product candidates including four distinct compounds. KALY has completed the first stage of clinical development and testing for a Chronic Obstructive Pulmonary Disease (COPD) therapy and is currently conducting phase one development and trials for compounds targeting Cancer Pain Management, Type 2 Diabetes and Epilepsy.
$170 Million Cannabis Therapeutics Market Opportunity
- Chronic Obstructive Pulmonary Disease (COPD) – The market for COPD treatment is anticipated to reach $14 billion by 2025;
- Type 2 Diabetes – The market for Type 2 Diabetes is expected to be a $64 billion market by 2026;
- Cancer Pain Management – The overall pain management treatment market is anticipated to reach $83 billion by 2024, and
- Epilepsy – The market for epilepsy treatment is anticipated to reach $9 billion by 2022.
$1 Million 2019 Revenue Target From Parallel Revenue Strategy
KALY is not relying on its biopharmaceutical development strategy alone to insure the company’s long-term success. With the popularity of cannabis extracts for infusion into various consumer products, KALY’s patented extraction process offers arguably the highest quality extract to the infusion market. Drawing on KALY’s patented cannabis extraction expertise, Puration’s EVERx CBD Sports Water is already the leading CBD infused beverage for the sports nutrition market. KALY has also introduced its own CBD confections line, Hemp4mula with CBD infused gum already on the market and gummies on the way. Hemp4mula is expected to be available on the Ecommerce site USMJ.com hosted by North American Cannabis Holdings, Inc. (aka USMJ). KALY has also entered into a partnership with Nouveau (USOTC: NOUV), a cannabis cultivation company, with plans to develop a proprietary cannabis cultivar that can further enhance the quality of KALY’s extracts. KALY’s consumer revenue strategy offers a business line that can stand alone, but one that also provides KALY with the long-term staying power to take the necessary time to bring its cannabis extract biopharmaceutical products to market. Currently, KALY management anticipates that its $1 million 2019 revenue goal for its parallel consumer market strategy is well within reach.
To learn more about the company visit https://www.kali-extracts.com/
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company’s actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.